Drug intelligence / Profile preview

deuteporfin

Development stage: Phase 1
Lead developer: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Administration: Intravenous

Overview

Deuteporfin is a novel photodynamic drug developed in China by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. It is designed for use in photodynamic therapy (PDT) and has demonstrated good photodynamic antitumor activity. The drug is administered intravenously and subsequently activated by laser light to exert its therapeutic effects.

Beyond the preview

Go deeper on deuteporfin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deuteporfin.

Explore the full profile